Drug Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Autoimmune Disease
Companies sign agreement to develop 2 novel treatments for autoimmune diseases
June 17th, 2005
Serono (SRA) and NovImmune (private) have signed an exclusive agreement under which NovImmune has granted Serono worldwide rights to develop and commercialize 2 of NovImmune's human monoclonal antibodies, NI-0401 and NI-0501, which may have therapeutic potential in a range of autoimmune diseases. NI-0401 targets the CD3 antigen, a key regulator in the activation of T-cells. The proliferation of activated T-cells is a hallmark of many autoimmune diseases, including insulin-dependent diabetes, Crohn disease, multiple sclerosis and rheumatoid arthritis, and of organ transplant rejection. NI-0501 targets interferon-gamma, a key cytokine involved in the...
Source: Drug Week (2005-06-17)
|
